BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

644 related articles for article (PubMed ID: 19409053)

  • 1. CD133 as a marker for cancer stem cells: progresses and concerns.
    Wu Y; Wu PY
    Stem Cells Dev; 2009 Oct; 18(8):1127-34. PubMed ID: 19409053
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Research progression of CD133 as a marker of cancer stem cells.
    Zhang H; Li SY
    Chin J Cancer; 2010 Mar; 29(3):243-7. PubMed ID: 20193104
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The utility and limitations of glycosylated human CD133 epitopes in defining cancer stem cells.
    Bidlingmaier S; Zhu X; Liu B
    J Mol Med (Berl); 2008 Sep; 86(9):1025-32. PubMed ID: 18535813
    [TBL] [Abstract][Full Text] [Related]  

  • 4. How powerful is CD133 as a cancer stem cell marker in brain tumors?
    Cheng JX; Liu BL; Zhang X
    Cancer Treat Rev; 2009 Aug; 35(5):403-8. PubMed ID: 19369008
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Isolation, characterization and mobilization of prostate cancer tissue derived CD133+ MDR1+ cells.
    Rentala S; Mangamoori LN
    J Stem Cells; 2010; 5(2):75-81. PubMed ID: 22049617
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD133: molecule of the moment.
    Mizrak D; Brittan M; Alison M
    J Pathol; 2008 Jan; 214(1):3-9. PubMed ID: 18067118
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DDX4 (DEAD box polypeptide 4) colocalizes with cancer stem cell marker CD133 in ovarian cancers.
    Kim KH; Kang YJ; Jo JO; Ock MS; Moon SH; Suh DS; Yoon MS; Park ES; Jeong N; Eo WK; Kim HY; Cha HJ
    Biochem Biophys Res Commun; 2014 May; 447(2):315-22. PubMed ID: 24727449
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cancer stem cells in the central nervous system--a critical review.
    Prestegarden L; Enger PØ
    Cancer Res; 2010 Nov; 70(21):8255-8. PubMed ID: 20959482
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cells with characteristics of cancer stem/progenitor cells express the CD133 antigen in human endometrial tumors.
    Rutella S; Bonanno G; Procoli A; Mariotti A; Corallo M; Prisco MG; Eramo A; Napoletano C; Gallo D; Perillo A; Nuti M; Pierelli L; Testa U; Scambia G; Ferrandina G
    Clin Cancer Res; 2009 Jul; 15(13):4299-311. PubMed ID: 19509143
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cancer stem cell marker CD133+ tumour cells and clinical outcome in rectal cancer.
    Wang Q; Chen ZG; Du CZ; Wang HW; Yan L; Gu J
    Histopathology; 2009 Sep; 55(3):284-93. PubMed ID: 19723143
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro identification and characterization of CD133(pos) cancer stem-like cells in anaplastic thyroid carcinoma cell lines.
    Zito G; Richiusa P; Bommarito A; Carissimi E; Russo L; Coppola A; Zerilli M; Rodolico V; Criscimanna A; Amato M; Pizzolanti G; Galluzzo A; Giordano C
    PLoS One; 2008; 3(10):e3544. PubMed ID: 18958156
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Limits of CD133 as a marker of glioma self-renewing cells.
    Clément V; Dutoit V; Marino D; Dietrich PY; Radovanovic I
    Int J Cancer; 2009 Jul; 125(1):244-8. PubMed ID: 19350631
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting CD133 antigen in cancer.
    Ferrandina G; Petrillo M; Bonanno G; Scambia G
    Expert Opin Ther Targets; 2009 Jul; 13(7):823-37. PubMed ID: 19530986
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of CD133 in synovial sarcoma.
    Terry J; Nielsen T
    Appl Immunohistochem Mol Morphol; 2010 Mar; 18(2):159-65. PubMed ID: 19752721
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD133 as a marker for regulation and potential for targeted therapies in glioblastoma multiforme.
    Choy W; Nagasawa DT; Trang A; Thill K; Spasic M; Yang I
    Neurosurg Clin N Am; 2012 Jul; 23(3):391-405. PubMed ID: 22748652
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The cancer stem cell marker CD133 has high prognostic impact but unknown functional relevance for the metastasis of human colon cancer.
    Horst D; Scheel SK; Liebmann S; Neumann J; Maatz S; Kirchner T; Jung A
    J Pathol; 2009 Dec; 219(4):427-34. PubMed ID: 19621338
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD133/CD166/Ki-67 triple immunofluorescence assessment for putative cancer stem cells in colon carcinoma.
    Mărgaritescu C; Pirici D; Cherciu I; Bărbălan A; Cârtână T; Săftoiu A
    J Gastrointestin Liver Dis; 2014 Jun; 23(2):161-70. PubMed ID: 24949608
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunohistochemical expression of cancer stem cell related markers CD44 and CD133 in endometrial cancer.
    Elbasateeny SS; Salem AA; Abdelsalam WA; Salem RA
    Pathol Res Pract; 2016 Jan; 212(1):10-6. PubMed ID: 26608413
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Isolation and characterization of CD133+ cell population within human primary and metastatic colon cancer.
    Puglisi MA; Sgambato A; Saulnier N; Rafanelli F; Barba M; Boninsegna A; Piscaglia AC; Lauritano C; Novi ML; Barbaro F; Rinninella E; Campanale C; Giuliante F; Nuzzo G; Alfieri S; Doglietto GB; Cittadini A; Gasbarrini A
    Eur Rev Med Pharmacol Sci; 2009 Mar; 13 Suppl 1():55-62. PubMed ID: 19530513
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transcriptional repression of cancer stem cell marker CD133 by tumor suppressor p53.
    Park EK; Lee JC; Park JW; Bang SY; Yi SA; Kim BK; Park JH; Kwon SH; You JS; Nam SW; Cho EJ; Han JW
    Cell Death Dis; 2015 Nov; 6(11):e1964. PubMed ID: 26539911
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.